[ad_1]
A large phase 3 study testing a candidate vaccine against COVID-19, being developed by pharmaceutical company AstraZeneca and the University of Oxford, has been suspended due to a suspected serious adverse reaction in a participant in the United Kingdom. site ‘Stat News’ this Tuesday.
(You may be interested: Why authorities in China say they ‘defeated’ coronavirus outbreak)
One of the participants suffers from “a potentially unexplained illness”a company spokesperson reported to the US media.
“This is a routine action that happens whenever there is a potentially unexplained disease in one of the trials while it is being investigated, ensuring that the integrity of the studies is maintained,” the spokesperson told CNBC and the specialized media. ‘Stat News’.
The company’s “standard review process caused a pause in vaccination to allow for review of safety data.”the spokesperson also noted.
(Also read: Downward trend in deaths from covid-19 in Colombia continues)
It was not immediately clear who determined the suspension, although it is possible that AstraZeneca did so voluntarily and was not ordered by any regulatory agency.
The nature of the adverse reaction and when it happened were also not immediately known, although the participant is expected to recover, according to a person familiar with the matter.(News in development)
(Also: Argentine teacher dies from covid-19 while teaching at Zoom)
EL UNIVERSAL (MEXICO) / GDA
* With information from EFE
